INHIBRX BIOSCIENCES INC (INBX) Fundamental Analysis & Valuation

NASDAQ:INBX • US45720N1037

Current stock price

123.19 USD
+3.26 (+2.72%)
Last:

This INBX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. INBX Profitability Analysis

1.1 Basic Checks

  • In the past year INBX has reported negative net income.
  • In the past year INBX has reported a negative cash flow from operations.
  • INBX had negative earnings in 4 of the past 5 years.
  • INBX had a negative operating cash flow in each of the past 5 years.
INBX Yearly Net Income VS EBIT VS OCF VS FCFINBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

1.2 Ratios

  • Looking at the Return On Assets, with a value of -95.62%, INBX is doing worse than 74.42% of the companies in the same industry.
  • INBX's Return On Equity of -1752.22% is on the low side compared to the rest of the industry. INBX is outperformed by 82.17% of its industry peers.
Industry RankSector Rank
ROA -95.62%
ROE -1752.22%
ROIC N/A
ROA(3y)253.19%
ROA(5y)131.06%
ROE(3y)-347.91%
ROE(5y)-289.95%
ROIC(3y)N/A
ROIC(5y)N/A
INBX Yearly ROA, ROE, ROICINBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1K -1K

1.3 Margins

  • INBX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INBX Yearly Profit, Operating, Gross MarginsINBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200K 400K 600K 800K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. INBX Health Analysis

2.1 Basic Checks

  • INBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • INBX has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, INBX has less shares outstanding
  • INBX has a worse debt/assets ratio than last year.
INBX Yearly Shares OutstandingINBX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
INBX Yearly Total Debt VS Total AssetsINBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 3.02 indicates that INBX is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.02, INBX is in the better half of the industry, outperforming 68.02% of the companies in the same industry.
  • A Debt/Equity ratio of 12.58 is on the high side and indicates that INBX has dependencies on debt financing.
  • The Debt to Equity ratio of INBX (12.58) is worse than 83.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 12.58
Debt/FCF N/A
Altman-Z 3.02
ROIC/WACCN/A
WACC9.79%
INBX Yearly LT Debt VS Equity VS FCFINBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 3.93 indicates that INBX has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 3.93, INBX is in line with its industry, outperforming 47.29% of the companies in the same industry.
  • INBX has a Quick Ratio of 3.93. This indicates that INBX is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of INBX (3.93) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.93
Quick Ratio 3.93
INBX Yearly Current Assets VS Current LiabilitesINBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. INBX Growth Analysis

3.1 Past

  • INBX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -107.65%.
  • The Revenue has grown by 550.00% in the past year. This is a very strong growth!
  • Measured over the past years, INBX shows a very negative growth in Revenue. The Revenue has been decreasing by -36.80% on average per year.
EPS 1Y (TTM)-107.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.72%
Revenue 1Y (TTM)550%
Revenue growth 3Y-15.96%
Revenue growth 5Y-36.8%
Sales Q2Q%-100%

3.2 Future

  • INBX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.75% yearly.
  • INBX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 170.20% yearly.
EPS Next Y38.35%
EPS Next 2Y29.83%
EPS Next 3Y23.71%
EPS Next 5Y16.75%
Revenue Next Year-100%
Revenue Next 2Y544.8%
Revenue Next 3Y402.6%
Revenue Next 5Y170.2%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INBX Yearly Revenue VS EstimatesINBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 50M 100M 150M 200M
INBX Yearly EPS VS EstimatesINBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 20 40 60 80 100

More info and screens

Find the best growth stocksShow best growing peers

1

4. INBX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for INBX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INBX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INBX Price Earnings VS Forward Price EarningsINBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INBX Per share dataINBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

  • A more expensive valuation may be justified as INBX's earnings are expected to grow with 23.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.83%
EPS Next 3Y23.71%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. INBX Dividend Analysis

5.1 Amount

  • INBX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INBX Fundamentals: All Metrics, Ratios and Statistics

INHIBRX BIOSCIENCES INC

NASDAQ:INBX (4/24/2026, 2:04:56 PM)

123.19

+3.26 (+2.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-19
Earnings (Next)05-12
Inst Owners74.06%
Inst Owner Change-0.12%
Ins Owners15.5%
Ins Owner Change0%
Market Cap1.80B
Revenue(TTM)1.30M
Net Income(TTM)-140.06M
Analysts43.33
Price Target153 (24.2%)
Short Float %23.09%
Short Ratio10.3
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-14.85%
Min EPS beat(2)-30.11%
Max EPS beat(2)0.4%
EPS beat(4)3
Avg EPS beat(4)1.97%
Min EPS beat(4)-30.11%
Max EPS beat(4)34.31%
EPS beat(8)5
Avg EPS beat(8)437.75%
EPS beat(12)5
Avg EPS beat(12)283.25%
EPS beat(16)6
Avg EPS beat(16)208.38%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1150%
PT rev (3m)1150%
EPS NQ rev (1m)-48.05%
EPS NQ rev (3m)-48.05%
EPS NY rev (1m)-14.84%
EPS NY rev (3m)-14.84%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1384.47
P/FCF N/A
P/OCF N/A
P/B 225.17
P/tB 225.17
EV/EBITDA N/A
EPS(TTM)-9.04
EYN/A
EPS(NY)-5.57
Fwd EYN/A
FCF(TTM)-8.89
FCFYN/A
OCF(TTM)-8.88
OCFYN/A
SpS0.09
BVpS0.55
TBVpS0.55
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -95.62%
ROE -1752.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)253.19%
ROA(5y)131.06%
ROE(3y)-347.91%
ROE(5y)-289.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 12.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.25%
Cap/Sales 2.38%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.93
Quick Ratio 3.93
Altman-Z 3.02
F-Score2
WACC9.79%
ROIC/WACCN/A
Cap/Depr(3y)166.85%
Cap/Depr(5y)125.66%
Cap/Sales(3y)518.68%
Cap/Sales(5y)319.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-107.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.72%
EPS Next Y38.35%
EPS Next 2Y29.83%
EPS Next 3Y23.71%
EPS Next 5Y16.75%
Revenue 1Y (TTM)550%
Revenue growth 3Y-15.96%
Revenue growth 5Y-36.8%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y544.8%
Revenue Next 3Y402.6%
Revenue Next 5Y170.2%
EBIT growth 1Y59.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.24%
OCF growth 3YN/A
OCF growth 5YN/A

INHIBRX BIOSCIENCES INC / INBX Fundamental Analysis FAQ

What is the fundamental rating for INBX stock?

ChartMill assigns a fundamental rating of 2 / 10 to INBX.


What is the valuation status for INBX stock?

ChartMill assigns a valuation rating of 1 / 10 to INHIBRX BIOSCIENCES INC (INBX). This can be considered as Overvalued.


Can you provide the profitability details for INHIBRX BIOSCIENCES INC?

INHIBRX BIOSCIENCES INC (INBX) has a profitability rating of 0 / 10.